Pulmonary Graft versus Host Disease after Hematopoietic Cell Transplantation: Where do we Stand in 2019?

Guang-Shing Cheng, MD
Associate Member, Clinical Research Division, Section of Pulmonary and Critical Care Medicine
Fred Hutchinson Cancer Research Center
Assistant Professor, Division of Pulmonary, Critical Care and Sleep Medicine
University of Washington
Wednesday, September 18, 2019, 3-4 pm
Fitkin Amphitheatre

Moderator: Jennifer Possick, MD
There is no corporate support for this activity
This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
Attending physicians, house staff/fellows, medical students, nurses, physician assistants.

NEEDS ASSESSMENT
1. Survivors of hematopoietic cell transplantation (HCT) are increasing, and late pulmonary complications associated with chronic graft-versus-host disease (GVHD) has emerged as a significant unmet clinical need, acknowledged by multidisciplinary subspecialty groups. The need for additional education about these complications has been recognized by clinicians at NIH, American Thoracic Society, Chest, European Respiratory Society, American Society of Bone Marrow Transplantation, and European Bone Marrow Society, evidenced by the lectures and special interest groups that have arisen around this topic.
2. Early recognition of bronchiolitis obliterans syndrome (pulmonary GVHD) after allogeneic hematopoietic cell transplantation is necessary to avert significant morbidity/mortality associated with this condition.
3. Because BOS after HCT is relatively rare, clinicians need to be updated with regard to current evidence-based treatment and management strategies.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will learn to:
1. Understand the scope and significance of pulmonary disease after allogeneic hematopoietic cell transplantation.
2. Understand the epidemiology, risk factors, and diagnostic criteria of bronchiolitis obliterans syndrome (BOS) after hematopoietic cell transplantation.

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
Richard Matthay, MD, Course Director – No conflicts of interest
Guang-Shing Cheng, MD – No conflicts of interest

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.